Evidence map›Paper›PMID 42193144›Full record

ArticleCurrent issues in molecular biology2026

Necroptosis in SJS/TEN:

Chandana Sooranahalli, Charles Bouchard, Omer Iqbal

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chandana SooranahalliDepartment of Ophthalmology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.ORCID 0009-0003-7445-7142
Charles BouchardDepartment of Ophthalmology, Loyola University Medical Center, Maywood, IL 60153, USA.
Omer IqbalDepartments of Ophthalmology & Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.ORCID 0000-0002-0791-6957

Funding

Illinois Society for Prevention of Blindness A809090
6 · The paper itself

Abstract

Necroptosis has been implicated in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), with prior studies demonstrating tissue-level involvement of receptor-interacting protein kinases RIPK1 and RIPK3. However, their systemic expression in the circulatory compartment remains incompletely characterized. The objective of this study is to evaluate circulating levels of RIPK1 and RIPK3 in patients with SJS/TEN and explore their potential association with diseases. Serum samples from patients with SJS/TEN and control groups were analyzed for RIPK1 and RIPK3 levels using ELISA. Group differences were assessed using non-parametric statistical methods. Circulating levels of RIPK1 and RIPK3 were elevated in patients with SJS/TEN compared with controls. These findings were consistent across analyses; however, variability within groups and overlap between cohorts were observed. These results suggest an association between increased circulating RIPK1 and RIPK3 levels and SJS/TEN. Given the limited sample size, heterogeneous control populations, and lack of functional or phosphorylation-specific assays, these findings should be considered exploratory. Further studies incorporating larger cohorts and mechanistic validation are needed to clarify the role of necroptosis-related pathways in the systemic manifestations of SJS/TEN.

Indexed as

cell death pathwayscytokines in SJS/TENimmune response in skin disordersinflammatory pathways in SJS/TENnecroptosisRIPK1RIPK3severe cutaneous adverse reactions (SCARs)SJS/TEN pathogenesisStevens–Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)

Identifiers

PMID42193144
PMCPMC13204834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.